Mammography may be the most recognizable — and singularly effective — type of personalized medicine, benefitting from digital developments that have taken shape over the past 16 years. Recently published literature attributes a reduction in breast cancer deaths up to 28 percent.1 Yet mammography is not the only way to personalize medicine. And it certainly is not the only one that can benefit from the development of advanced technologies.
As we prepare to enter the age of value medicine, with its implicit reliance on increasingly personalized approaches, new developments and consequent improvement of diagnostic and therapeutic techniques demand innovation. What wonders of medical imaging might be unlocked if the status quo is challenged?
One such challenge only now beginning to take shape is GLINT (glucoCEST imaging of neoplastic tumors), a magnetic resonance (MR) based technique being developed to visualize the body’s use of glucose. It’s too early to tell whether this new technology can be effectively applied to cancer screening. It is only a few months old, its development having been formally announced earlier this year. But one thing is for sure, the approach is relevant to personalized healthcare.
GLINT imaging is based on the use by tumors of massive amounts of glucose. This concept underlies the ability of positron emission tomography (PET) to spot the presence and recurrence of tumors. But, whereas PET exposes patients to ionizing radiation through the use of glucose molecules tagged with positron-emitting fluorine (as well as the computed tomography (CT) with which it is commonly paired), GLINT records hot spots coming from the use of non-labeled glucose.
At the very least, the molecular imaging aspect of GLINT raises the potential for its use in a concerted effort against cancer. Therein lies the true potential of medical imaging in the future, and specifically its role in personalized medicine.
Beyond Medicine’s Grasp
The realization of personalized healthcare has been elusive. A decade ago it appeared near at hand with the sequencing of the human genome, which was supposed to provide a blueprint for how to make diagnostic and therapeutic medicine more exact. When that didn’t pan out, the concept of personalized medicine was redefined as healthcare tailored to the individual by whatever means could be found.
Just as mammography has proven useful in women’s health, so might the development of effective tests for diagnosing and monitoring prostate cancer be useful in men’s health. A large American study has found that screening for prostate cancer has not reduced the chance of dying from the disease.2
The means for impacting morbidity from this disease is badly needed. According to the U.S. government, prostate cancer is the most common non-skin cancer and the second leading cause of cancer-related death in men in the United States. It was estimated that, in 2014, 233,000 men in the U.S. would be diagnosed with prostate cancer. Nearly 29,500 would die of the disease.
Prostate Screening Potential
This bleak picture exists despite the many technologies that are being leveled against this cancer, technologies that include blood tests for prostate specific antigen (PSA),
ultrasound and ultrasound-guided biopsy.
Lately an advanced form of prostate MR has been commercialized, one that is noninvasive thanks to a surface coil that streamlines patient set-up and accelerates scans. Adding to the future potential of prostate assessment are several PET radiotracers that show promise for identifying prostate cancer, metastatic spread and relapse. Notably new opportunities are also arising in SPECT, just as research has determined that blood, tissue and urine samples may contain better biomarkers than PSA.
In the end, however, improved healthcare will come down to more than hard work and possibilities. It will depend on evidence indicating the specific utility of new technologies.
This evidence might be obtained through data mining, a capability that promises to quantify experience, offering objective evidence to support the development and use of new and advanced technologies. Data mining could expand substantially once enterprise imaging takes hold and the data collected about patients expands.
Clearly, then, the potential of personalized medicine cannot be achieved through a single magic bullet but through a bombardment of such bullets, all precisely aimed so as to bring practitioners closer to the truth about disease as it affects the individual — and the therapy that will precisely impact it.
Additional reading:
1. Weedon-Fekjær H, Romundstad PR, et al. Modern mammography screening and breast cancer mortality: population study. BMJ 2014; 348
2. Andriole GL, Crawford ED, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J National Cancer Institute 2012; 104:125
Editor’s note: This column is the culmination of a series of four blogs by industry consultant Greg Freiherr on screening. The blogs, “Screening: How New Looks at Old Modalities Might Turn Imaging Upside Down,” “Why Developing Multiple Screening Technologies is a Must,” “How the Trump Candidacy Might
Energize Men’s Healthcare” and “How Data Mining Can Personalize the Practice of Medicine” can be found at
www.itnonline.com/content/screening.
February 13, 2026 
